Dova Pharmaceuticals Inc (NASDAQ:DOVA) traded up 18.5% during trading on Monday . The company traded as high as $18.22 and last traded at $17.89, 1,181,655 shares changed hands during trading. An increase of 367% from the average session volume of 253,215 shares. The stock had previously closed at $15.10.
A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub cut shares of Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 17th. HC Wainwright boosted their target price on shares of Dova Pharmaceuticals from $39.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Oppenheimer started coverage on shares of Dova Pharmaceuticals in a report on Thursday, August 29th. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a report on Friday, July 12th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the stock. Dova Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $25.43.
The stock has a market capitalization of $434.91 million, a price-to-earnings ratio of -7.97 and a beta of 2.57. The firm’s fifty day moving average is $15.54 and its 200-day moving average is $12.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.64 and a quick ratio of 5.37.
In related news, Director Paul B. Manning purchased 28,062 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were purchased at an average cost of $15.87 per share, with a total value of $445,343.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jason Hoitt sold 2,387 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $13.81, for a total transaction of $32,964.47. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 610,916 shares of company stock worth $8,689,169 and sold 27,807 shares worth $422,464. Corporate insiders own 60.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in DOVA. DekaBank Deutsche Girozentrale increased its stake in Dova Pharmaceuticals by 22.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after purchasing an additional 2,400 shares during the last quarter. FMR LLC increased its stake in Dova Pharmaceuticals by 0.8% during the first quarter. FMR LLC now owns 1,347,521 shares of the company’s stock valued at $11,979,000 after purchasing an additional 10,970 shares during the last quarter. Sanders Morris Harris LLC increased its stake in Dova Pharmaceuticals by 85.1% during the second quarter. Sanders Morris Harris LLC now owns 521,887 shares of the company’s stock valued at $7,359,000 after purchasing an additional 239,972 shares during the last quarter. SG Americas Securities LLC bought a new stake in Dova Pharmaceuticals during the second quarter valued at $604,000. Finally, Capital Investment Advisory Services LLC increased its stake in Dova Pharmaceuticals by 222.2% during the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock valued at $45,000 after purchasing an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 32.18% of the company’s stock.
About Dova Pharmaceuticals (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Recommended Story: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.